Monopar Therapeutics (MNPR) Stock Price & Analysis
Monopar Therapeutics (MNPR) rose 0.03% to USD 60.63 as of June 10, 2026 at 01:57 UTC, according to Nexqual real-time market data.
MNPR last closed at USD 60.61; the session ranged USD 58.3–62.23 on volume of 166,922 shares. Market capitalization is $406.16M, with a 52-week range of USD 29.18–105 (NCM). Source: Nexqual, June 10, 2026 at 01:57 UTC.
Key Statistics (as of June 10, 2026 at 01:57 UTC)
| Price | USD 60.63 |
|---|---|
| Change | ▲ 0.03% (up) |
| Previous Close | USD 60.61 |
| Open | USD 59.3 |
| Day Range | USD 58.3 – 62.23 |
| 52-Week Range | USD 29.18 – 105 |
| Volume | 166,922 shares |
| Market Cap | $406.16M |
| Exchange | NCM |
Technical Analysis (MNPR)
Nexqual's technical model rates MNPR "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 01:57 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 52.69 (neutral) |
| vs SMA50 | Above (USD 58.21) |
| MACD | 0.64 (positive) |
Analyst Ratings (MNPR)
Wall Street analysts rate MNPR "Strong Buy" based on 13 analysts, with a mean price target of USD 112.62 (range USD 100–130), per Nexqual as of June 10, 2026 at 01:57 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 112.62 |
| High Target | USD 130 |
| Low Target | USD 100 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (MNPR)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.65 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.46 vs est -0.9 ▲ beat |
| 2025-12-31 | USD -0.61 vs est -0.51 ▼ miss |
| 2025-09-30 | USD -0.48 vs est -0.4 ▼ miss |
| 2025-06-30 | USD -0.35 vs est -0.48 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
Financials & Fundamentals (MNPR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -15.86% |
| Debt / Equity | 0.17 |
| Current Ratio | 56.05 |
| Total Cash | $137.49M |
| Total Debt | $230,425 |
| Free Cash Flow | $-5.38M |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
Financial Health Score (MNPR)
Nexqual rates Monopar Therapeutics's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $137M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M |
| Efficiency | Critical — ROE -16%, ROA -12.1% |
Ownership (MNPR)
| Insider Ownership | +23.23% |
|---|---|
| Institutional Ownership | +93.28% |
| Shares Outstanding | 6.70M |
| Float | 4.13M |
| Short % of Float | +34.53% |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
Leadership (MNPR)
Monopar Therapeutics is led by Chandler D. Robinson M.B.A., M.D., M.Sc. (age 41), Co-Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 01:57 UTC.
| Co-Founder, CEO, President & Director | Chandler D. Robinson M.B.A., M.D., M.Sc. (age 41) |
|---|---|
| Co-Founder & Independent Executive Chairman of the Board | Christopher M. Starr (age 73) |
| CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer | Quan Anh Vu (age 53) |
| Chief Operating Officer | Andrew J. Cittadine (age 53) |
Major Backers & Investors (MNPR)
Notable institutional backers of Monopar Therapeutics include Janus Henderson Group PLC, RA Capital Management, L.P., Saturn V Capital Management LP, according to Nexqual as of June 10, 2026 at 01:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 19.67% |
| RA Capital Management, L.P. | 9.96% |
| Saturn V Capital Management LP | 5.16% |
| Deerfield Management Company, L.P | 4.83% |
| Adage Capital Partners GP L.L.C. | 4.62% |
| Siren, L.L.C. | 4.03% |
| Adar1 Capital Management, LLC | 3.95% |
| Polar Capital Holdings PLC | 3.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.83% |
| Vanguard Group | 6.77% |
Source: Nexqual, June 10, 2026 at 01:57 UTC.
From Monopar Therapeutics's Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
- The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
- It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
- The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
| BCDA | BioCardia, Inc. | USD 0.86 | ▼ 16.5% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.17 | ▼ 12.55% |
| PBLA | Panbela Therapeutics, Inc. | USD 0.01 | ▲ 0% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:57 UTC. This page is informational and not investment advice.